Fierce Biotech1 min read
saveAnthropic board director Vas Narasimhan bets AI can help Novartis solve ‘biological latency’
On the same day Anthropic staged a record-shattering IPO on Nasdaq, the artificial intelligence tech giant’s lone pharmaceutical board member, Novartis CEO Vas Narasimhan, was in London pitching investors on how the Swiss drugmaker is using AI to shrink drug development timelines and one day solve “biological latency.”
comments(0)
5-min edit window · permanent after that